# Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma

> **NCT06960382** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Zurich** · enrollment: 36 (estimated)

## Conditions studied

- Allergic Rhinitis
- Allergic Asthma

## Interventions

- **DRUG:** ALUTARD SQ® Felis domesticus

## Key facts

- **NCT ID:** NCT06960382
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2027-05-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06960382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06960382, "Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06960382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*